Resonant Clinical Solutions Launches Asset Management Suite
New programs provide structured regulatory and infrastructure support for increasingly complex clinical trial pipelines.
Updated on Oct. 29, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to properly handle and store critical medical research samples?
Resonant Clinical Solutions has launched a suite of three asset management programs designed to handle research inventory across complex clinical trials. The service is currently available for life sciences organizations to manage growing sample pipelines.
Why it matters
As clinical research shifts toward complex cell and gene therapies, organizations are struggling to manage massive sample volumes across fragmented global sites. This platform provides a centralized infrastructure to maintain regulatory compliance and inventory visibility for researchers.
Resonant Clinical Solutions currently oversees a portfolio of 100 million research assets and has facilitated more than 20,000 site shipments. These figures represent the company's current scale across 2,500 clinical trials.
The players
Resonant Clinical Solutions
A life sciences infrastructure firm that employs 850 people and manages biological research assets for clinical trials.
The details
The program suite, which includes Remote, Proactive, and Strategic Asset Management, functions by conducting an initial audit of a client's existing inventory. The company then assigns the appropriate infrastructure and regulatory oversight model based on the complexity and scope of the client's clinical pipeline.
Timeline
October 29, 2026: Resonant Clinical Solutions announced the new program suite at the ISBER International Biospecimen Summit.
The Tech Race
The launch reflects an industry-wide scramble to automate sample management as pipelines shift toward high-stakes cell and gene therapies. This moves competitive pressure toward companies that can guarantee strict regulatory compliance across fragmented international trial sites.
Life sciences organizations can now engage these tiers of inventory management to offload administrative and regulatory burdens related to sample storage. Initial access to these programs is now available through the company's established clinical operations in the U.S., U.K., and Europe.
The takeaway
The move underscores the growing need for specialized logistics in modern drug development where the volume of samples often outpaces internal management capabilities. Researchers should monitor the firm's expansion of site-specific support to see how it scales against rising global shipment demands.
Further reading
For broader trends in research infrastructure, see our latest coverage in Biotech.
More information
Review the full sample asset management program information to assess service compatibility.
Source note: This article includes information reported by Adnkronos.
Live Poll
Do you trust pharmaceutical companies to properly handle and store critical medical research samples?
